摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-bromo-4-(5-bromo-2-methoxyphenyl)-5-(4-bromobenzyl)-5-hydroxy-1-isobutylpyrrol-2(5H)-one | 1561859-16-2

中文名称
——
中文别名
——
英文名称
3-bromo-4-(5-bromo-2-methoxyphenyl)-5-(4-bromobenzyl)-5-hydroxy-1-isobutylpyrrol-2(5H)-one
英文别名
3-Bromo-4-(5-bromo-2-methoxyphenyl)-5-[(4-bromophenyl)methyl]-5-hydroxy-1-(2-methylpropyl)pyrrol-2-one;3-bromo-4-(5-bromo-2-methoxyphenyl)-5-[(4-bromophenyl)methyl]-5-hydroxy-1-(2-methylpropyl)pyrrol-2-one
3-bromo-4-(5-bromo-2-methoxyphenyl)-5-(4-bromobenzyl)-5-hydroxy-1-isobutylpyrrol-2(5H)-one化学式
CAS
1561859-16-2
化学式
C22H22Br3NO3
mdl
——
分子量
588.134
InChiKey
TUWHLEDJGWKXEP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-bromo-4-(5-bromo-2-methoxyphenyl)-5-(4-bromobenzyl)-5-hydroxy-1-isobutylpyrrol-2(5H)-one对甲苯磺酸 作用下, 以 氯仿 为溶剂, 反应 2.0h, 以23%的产率得到(Z)-3-bromo-4-(5-bromo-2-methoxyphenyl)-5-(4-bromobenzylidene)-1-isobutylpyrrol-2(5H)-one
    参考文献:
    名称:
    Inhibition of Enterococcus faecalis biofilm formation by highly active lactones and lactams analogues of rubrolides
    摘要:
    Seven beta-aryl substituted gamma-alkylidene-gamma-lactones analogues of rubrolides were synthesized from mucobromic acid and converted through a lactamization with isobutylamine into their corresponding gamma-hydroxy-gamma-lactams (76-85%). These lactams were converted into (Z)- and (E)-gamma-alkylidene-gamma-lactams (23 -45%). All compounds were fully characterized by IR, NMR (H-1 and C-13), COSY and HETCOR bidimensional experiments, and NOE difference spectroscopy experiments when necessary. Evaluation of these three different classes of compounds against Enterococcus faecalis biofilm formation showed that all classes are active and the highest biofilm inhibition activity was caused by lactam 13f (IC50 = 0.76 mu g/mL). Moreover, in almost all cases at least one of the lactams is more active than its correspondent gamma-alkylidene-gamma-lactone. The use of rubrolides as a lead structure has proven successful for the identification of new compounds displaying novel antibacterial activities, namely biofilm inhibition, which have the potential for the development of antimicrobial drugs targeted to inhibition of the initial stages of bacterial infections, rather than bacterial viability. Such drugs are less prompt to induce bacterial resistance, being therefore a more cost-effective investment for pharmaceutical research. (C) 2014 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2014.05.035
  • 作为产物:
    描述:
    3-bromo-4-(5-bromo-2-methoxyphenyl)furan-2(5H)-one 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 7.0h, 生成 3-bromo-4-(5-bromo-2-methoxyphenyl)-5-(4-bromobenzyl)-5-hydroxy-1-isobutylpyrrol-2(5H)-one
    参考文献:
    名称:
    Inhibition of Enterococcus faecalis biofilm formation by highly active lactones and lactams analogues of rubrolides
    摘要:
    Seven beta-aryl substituted gamma-alkylidene-gamma-lactones analogues of rubrolides were synthesized from mucobromic acid and converted through a lactamization with isobutylamine into their corresponding gamma-hydroxy-gamma-lactams (76-85%). These lactams were converted into (Z)- and (E)-gamma-alkylidene-gamma-lactams (23 -45%). All compounds were fully characterized by IR, NMR (H-1 and C-13), COSY and HETCOR bidimensional experiments, and NOE difference spectroscopy experiments when necessary. Evaluation of these three different classes of compounds against Enterococcus faecalis biofilm formation showed that all classes are active and the highest biofilm inhibition activity was caused by lactam 13f (IC50 = 0.76 mu g/mL). Moreover, in almost all cases at least one of the lactams is more active than its correspondent gamma-alkylidene-gamma-lactone. The use of rubrolides as a lead structure has proven successful for the identification of new compounds displaying novel antibacterial activities, namely biofilm inhibition, which have the potential for the development of antimicrobial drugs targeted to inhibition of the initial stages of bacterial infections, rather than bacterial viability. Such drugs are less prompt to induce bacterial resistance, being therefore a more cost-effective investment for pharmaceutical research. (C) 2014 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2014.05.035
点击查看最新优质反应信息

文献信息

  • Inhibition of Enterococcus faecalis biofilm formation by highly active lactones and lactams analogues of rubrolides
    作者:Ulisses A. Pereira、Luiz C.A. Barbosa、Célia R.A. Maltha、Antônio J. Demuner、Mohammed A. Masood、Andréa L. Pimenta
    DOI:10.1016/j.ejmech.2014.05.035
    日期:2014.7
    Seven beta-aryl substituted gamma-alkylidene-gamma-lactones analogues of rubrolides were synthesized from mucobromic acid and converted through a lactamization with isobutylamine into their corresponding gamma-hydroxy-gamma-lactams (76-85%). These lactams were converted into (Z)- and (E)-gamma-alkylidene-gamma-lactams (23 -45%). All compounds were fully characterized by IR, NMR (H-1 and C-13), COSY and HETCOR bidimensional experiments, and NOE difference spectroscopy experiments when necessary. Evaluation of these three different classes of compounds against Enterococcus faecalis biofilm formation showed that all classes are active and the highest biofilm inhibition activity was caused by lactam 13f (IC50 = 0.76 mu g/mL). Moreover, in almost all cases at least one of the lactams is more active than its correspondent gamma-alkylidene-gamma-lactone. The use of rubrolides as a lead structure has proven successful for the identification of new compounds displaying novel antibacterial activities, namely biofilm inhibition, which have the potential for the development of antimicrobial drugs targeted to inhibition of the initial stages of bacterial infections, rather than bacterial viability. Such drugs are less prompt to induce bacterial resistance, being therefore a more cost-effective investment for pharmaceutical research. (C) 2014 Elsevier Masson SAS. All rights reserved.
查看更多